UNSPSC 51142548: Budipine hydrochloride

This classification denotes an antiparkinson agent with the molecular formula C21H27N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NBF4Q9307Q, chemically known as 1-tert-butyl-4,4-diphenylpiperidine hydrochloride but more generally known as budipine hydrochloride, which bears US NIH Compound Identifier 3030419. European Medicines Agency schedules Budipine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35026.

Most nations, for tariff and trade purposes, schedule budipine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, BUDIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(C)N1CCC(CC1)(C2CCCCC2)C3CCCCC3.CL.

UNSPSC 51142548 Budipine hydrochloride is a Commodity code for a pharmaceutical active ingredient, but the recent state and local procurement activity associated with this code does not align with the pharmaceutical compound named. Seminole County, Florida posted the only recent opportunity on file under this code—an IFB for naloxone (an opioid antagonist) and safe drug deactivation systems, neither of which match budipine hydrochloride in therapeutic class or indication. The sourcing reflects community health and emergency response priorities rather than the scope implied by the code's nominal designation. State and local issuing bodies using this code appear limited to county health departments pursuing pharmaceutical or medical supply acquisitions, though the single opportunity provided does not establish a broader issuing-body pattern.

Seminole County's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement included E-Verify compliance, drug-free workplace certification, and standard commercial insurance requirements. The mismatch between the code assignment (budipine hydrochloride) and the actual goods procured (naloxone and deactivation systems) suggests either a data-entry error in the opportunity classification or a broad and unreliable tagging of pharmaceutical-related purchases to this specific commodity code. Given the single recent opportunity and its misalignment with the code's stated pharmaceutical active ingredient, activity under this code does not support reliable business development targeting at this time.